Colcibra Uses, Dosage, Side Effects, Food Interaction and all others data.

Colcibra is a nonsteroidal anti-inflammatory drug that exhibits anti-inflammatory, analgesic and antipyretic activities. The mechanism of action of Colcibra is believed to be due to inhibition of prostaglandin synthesis, primarily via inhibition of cyclooxygenase-2 (COX-2) and at therapeutic concentrations in humans, Colcibra does not inhibit the cyclooxygenase-1 (COX-1) isoenzyme.

Colcibra inhibits cyclooxygenase 2 (COX-2) enzyme, reducing pain and inflammation. It is important to note that though the risk of bleeding with celecoxib is lower than with certain other NSAIDS, it exists nonetheless and caution must be observed when it is administered to those with a high risk of gastrointestinal bleeding.

A note on the risk of cardiovascular events

Significant concerns regarding the safety of COX-2 selective NSAIDs emerged in the early 2000s. Rofecoxib, another member of the COX-2 inhibitor drug class, also known as Vioxx, was withdrawn from the market due to prothrombotic cardiovascular risks. Following an FDA Advisory Committee meeting in 2005, in which data from large clinical outcome trials were evaluated, the FDA concluded that the risk for cardiovascular thrombotic events for both COX-2 selective NSAIDs and nonselective NSAIDs was evident. It was determined that the benefits of celecoxib treatment, however, outweighed the risks. Postmarketing cardiovascular outcomes trial (PRECISION) revealed that the lowest possible dose of celecoxib was similar in cardiovascular safety to moderate strength doses of both naproxen and ibuprofen. Patients who had previous cardiovascular events including acute MI, coronary revascularization, or coronary stent insertion were not evaluated in the trial. It is not advisable to administer NSAIDS to these groups of patients.

Trade Name Colcibra
Availability Prescription only
Generic Celecoxib
Celecoxib Other Names Celecoxib, Célécoxib, Celecoxibum
Related Drugs Humira, Ubrelvy, Buprenex, Botox, aspirin, prednisone, ibuprofen, acetaminophen, tramadol, meloxicam
Type Capsule
Formula C17H14F3N3O2S
Weight Average: 381.372
Monoisotopic: 381.075882012
Protein binding

The protein binding of celecoxib is 97%, and it is primarily bound to albumin.

Groups Approved, Investigational
Therapeutic Class Drugs for Osteoarthritis, Drugs used for Rheumatoid Arthritis, Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Manufacturer Ranbaxy Laboratories (sun Pharma)
Available Country India
Last Updated: September 19, 2023 at 7:00 am


Colcibra used for relief of the signs and symptoms of osteoarthritis, for relief of the signs and symptoms of rheumatoid arthritis; for relief of pain after dental extraction; for reduction of colorectal polyps in Familial Adenomatous Polyposis (FAP)

Colcibra is also used to associated treatment for these conditions: Ankylosing Spondylitis (AS), Osteoarthritis (OA), Pain, Acute, Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile

How Colcibra works

Unlike most NSAIDs, which inhibit both types of cyclooxygenases (COX-1 and COX-2), celecoxib is a selective noncompetitive inhibitor of cyclooxygenase-2 (COX-2) enzyme. COX-2 is expressed heavily in inflamed tissues where it is induced by inflammatory mediators. The inhibition of this enzyme reduces the synthesis of metabolites that include prostaglandin E2 (PGE2), prostacyclin (PGI2), thromboxane (TXA2), prostaglandin D2 (PGD2), and prostaglandin F2 (PGF2). Resultant inhibition of these mediators leads to the alleviation of pain and inflammation.

By inhibiting prostaglandin synthesis, non-steroidal anti-inflammatory drugs (NSAIDs) cause mucosal damage, ulceration and ulcer complication throughout the gastrointestinal tract. Colcibra poses less of an ulceration risk than other NSAIDS, owing to its decreased effect on gastric mucosal prostaglandin synthesis when compared to placebo.

Colcibra exerts anticancer effects by binding to the cadherin-11 (CDH11)protein, which is thought to be involved in the progression of tumors, and inhibiting the 3-phosphoinositide-dependent kinase-1 (PDK-1) signaling mechanism. In addition, celecoxib has been found to inhibit carbonic anhydrase enzymes 2 and 3, further enhancing its anticancer effects.

As mentioned in the pharmacodynamics section of this drug entry, celecoxib may cause an increased risk of thrombotic events. The risk of thrombosis resulting from COX-2 inhibition is caused by the vasoconstricting actions of thromboxane A2, leading to enhanced platelet aggregation, which is uncontrolled when the actions of prostacyclin, a platelet aggregation inhibitor, are suppressed through the inhibition of COX-2.


Colcibra dosage

Osteoarthritis: The recommended oral dose is 200 mg per day administered as a single dose or as 100 mg twice daily.

Rheumatoid arthritis: The recommended oral dose is 100 to 200 mg twice daily.

Familial adenomatous polyposis (FAP): The recommended oral dose is 400 mg twice daily to be taken with food.

Dental pain: Single dose of Colcibra 100 mg to400 mg

Side Effects

Gastrointestinal side effects include abdominal pain, diarrhoea, dyspepsia, flatulence and nausea. Central nervous system side effects include dizziness, headache and insomnia. Other side effects include upper respiratory tract infection, skin rash, back pain and peripheral edema.


The oral TDLo in humans 5.71 mg/kg.

It is not advisable to administer celecoxib in patients with renal impairment or advanced hepatic impairment, as this may lead to increased serum concentrations, causing toxicity. Symptoms of overdose may include breathing difficulties, coma, drowsiness, gastrointestinal bleeding, high blood pressure, kidney failure, nausea, sluggishness, stomach pain, and vomiting. Because serious gastrointestinal tract ulceration and bleeding can occur without preceding symptoms, patients should be monitored for signs/symptoms of gastrointestinal bleeding. Symptomatic and supportive measures should be taken in a celecoxib overdose. The induction of emesis or administration of active charcoal should take place if the patient is seen within 4 hours of celecoxib ingestion. Diuresis, urinary alkalinization, hemodialysis, or hemoperfusion may not be useful in a celecoxib overdose due to its high level of protein binding.


Colcibra cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids. Colcibra should be prescribed with extreme caution in patients with a prior history of G.I. ulcer-disease or G.I. bleeding, hepatic and renal insufficiency, heart failure, those taking diuretics and ACE inhibitors, pre-existing asthma, elderly patients.


Furosemide: NSAIDs can reduce the matriuretic effect of furosemide and thiazides in some patients.

Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.

Warfarin: Caution should be exercised when administering Colcibra with warfarin since these patients are at increased risk of bleeding complications.

Food Interaction

  • Avoid alcohol. Alcohol increases the risk of gastrointestinal irritation.
  • Avoid multivalent ions. Separate the administration of aluminum and magnesium containing drugs by several hours.
  • Take with or without food. Doses up to 200 mg can be taken without regard to food, but doses of 400mg or higher should be taken with food.

Colcibra Hypertension interaction

[Moderate] Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.

NSAIDs should be used with caution in patients with hypertension.

Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.

Volume of Distribution

The apparent volume of distribution of celecoxib at steady state (Vss/F) is about 429 L, which suggests wide distribution into various tissues. Colcibra is not preferentially bound to red blood cells. Another resource reports a volume of distribution of 455 ± 166L.

Elimination Route

Colcibra is absorbed rapidly in the gastrointestinal tract. When a single oral dose of 200 mg was given to healthy research subjects, the peak plasma levels of celecoxib occurred within 3 hours. The Cmax is 705 ng/mL. When multiple doses are given, steady-state concentrations are reached on or before day 5. When taken with a high-fat meal, peak plasma levels are delayed for about 1 to 2 hours with an increase in total absorption (AUC) of 10% to 20%. The AUC of celecoxib has been shown to be significantly lower in patients with chronic renal impairment. A meta-analysis of pharmacokinetic studies has suggested an approximately 40% higher AUC (area under the curve) of celecoxib in black patients compared to Caucasians for unknown reasons.

Half Life

The effective half-life of celecoxib is approximately 11 hours when a single 200 mg dose is given to healthy subjects. The terminal half-life of celecoxib varies because of its low solubility, which prolongs absorption.


Apparent clearance (CL/F), single oral 200 mg dose, healthy subjects = 27.7 L/hr. Clearance may be decreased by about 47% in patients with chronic renal insufficiency, according to a pharmacokinetic study. Studies have not been performed in patients with severe renal impairment.

Elimination Route

Colcibra is primarily eliminated by hepatic metabolism with small amounts (12 About 57% of an oral dose of celecoxib is excreted in the feces and 27% is found to be excreted into the urine in the form of metabolites. The main metabolite in urine and feces is identified as the carboxylic acid metabolite (73%). The amount of glucuronide in the urine is reported to be low.

Pregnancy & Breastfeeding use

Colcibra should be used during pregnancy only if the potential benefit justifies the potential risk to fetus. But in late pregnancy Colcibra should be avoided because it may cause premature closure of ductus arteriosus.

It is not known whether Colcibra is excreted in human milk. Because many drugs are excreted in human milk and because of potential for serious adverse reactions in nursing infants from Colcibra, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.


Colcibra is contraindicated in patients with known hypersensitivity to Colcibra, who have demonstrated allergic type reactions to sulfonamide or who have experienced asthma, urticaria or allergic type reactions after taking aspirin or other NSAIDs.

Special Warning

Geriatric: Dose adjustment in the elderly is not generally necessary. However, for patients of less than 50 kg in body weight, initiate therapy at the lowest recommended dose.

Paediatric: The safety and efficacy of Colcibra is not established in paediatric patients.

Hepatic insufficiency: Colcibra should be introduced at a reduced dose in patients with moderate hepatic impairment. The use of Colcibra in patients with severe hepatic impairment is not recommended.

Acute Overdose

Patients should be managed by symptomatic and supportive care following an NSAID overdose. No specific antidote is available.

Storage Condition

Store at 15 to 30° C.

Innovators Monograph

You find simplified version here Colcibra

Colcibra contains Celecoxib see full prescribing information from innovator Colcibra Monograph, Colcibra MSDS, Colcibra FDA label


What is Colcibra used for?

It is used to treat the pain and inflammation in osteoarthritis, acute pain in adults, rheumatoid arthritis, ankylosing spondylitis, painful menstruation, and juvenile rheumatoid arthritis.

How safe is Colcibra?

Colcibra is no less safe than two other non-opioid painkillers. A prescription painkiller that has been under a cloud for more than a decade is apparently safer than previously believed, a Food and Drug Administration panel concluded Wednesday.

How does Colcibra work?

Colcibra works by stopping the body's production of a substance that causes pain and inflammation.

What are the common side effects of Colcibra?

Common side effects of Colcibra are include:

  • stomach pain, heartburn, gas, diarrhea, constipation, nausea, vomiting;
  • swelling in your hands or feet;
  • dizziness; or.
  • cold symptoms such as stuffy nose, sneezing, sore throat.

Is Colcibra safe during pregnancy?

Colcibra should not be used during pregnancy. Women who could get pregnant should use an effective method of contraception to prevent pregnancy while taking Colcibra. If you think you could be pregnant, stop taking Colcibra and consult your doctor.

Is Colcibra safe during breastfeeding?

Because of the low levels of Colcibra in breastmilk, amounts ingested by the infant are small and would not be expected to cause any adverse effects in breastfed infants. No special precautions are required.

Can I drink alcohol with Colcibra?

Alcohol should be avoided if taking Colcibra, in particular, because the medication already causes a higher risk of cardiovascular side effects, such as heart attacks and strokes, and alcohol increases that risk.

Can I drive after taking Colcibra?

If you become drowsy, dizzy or light-headed after taking Colcibra, do not drive or operate machinery.

Is Colcibra used for back pain?

Colcibra treats the pain, inflammation, and stiffness.

Is Colcibra bad for kidneys?

Clinical Inquiry concludes that Colcibra does not appear to worsen renal function, it should still be used with caution for patients who are elderly, hospitalized, or at risk of developing serious complications such as acute renal failure, heart failure, and gastrointestinal bleeding.

Can Colcibra make me sleepy?

Colcibra oral capsule does not cause drowsiness, but it can cause other side effects.

Is it safe to take Colcibra every day?

Colcibra may be taken at any time without regard to meals, particularly with lower doses (such as up to 200 mg twice daily). Higher doses (such as 400 mg twice daily) should be taken with food to reduced stomach upset.

How long does Colcibra stay in my system?

The half-life of Colcibra is about 11 to 12 hours which means that it is expelled from the body within about 2 1/2 to 3 days after discontinuing the medicine.

What is the best time of day to take Colcibra?

Colcibra may be taken at any time without regard to meals, particularly with lower doses (such as up to 200 mg twice daily). Higher doses (such as 400 mg twice daily) should be taken with food to reduced stomach upset.

How often can I take Colcibra?

Colcibra capsules are usually taken once or twice a day.

How long does Colcibra take to work?

Colcibra takes approximately 3 hours after oral administration to reach peak concentrations. The pain-relieving effects of Colcibra last for approximately 12 hours.

How long does Colcibra stay in my system?

The half-life of Colcibra is about 11 to 12 hours which means that it is expelled from the body within about 2 1/2 to 3 days after discontinuing the medicine.

Can I take Colcibra for a long time?

For safe and effective use of this Colcibra, do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered.

Who should not take Colcibra?

You should not take Colcibra if you have high blood pressure, a heart attack, chronic heart failure, abnormal bleeding in the brain resulting in damage to brain tissue, called a hemorrhagic stroke.

What happen If I missed dose of Colcibra?

If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

What happen if I take too much Colcibra?

If you take too much Colcibra call your healthcare provider or local Poison Control Center, or seek emergency medical attention right away. If Colcibra is administered by a healthcare provider in a medical setting, it is unlikely that an overdose will occur. However, if overdose is suspected, seek emergency medical attention.

What happens if I suddenly stop taking Colcibra?

Suddenly stopping your treatment with Colcibra may lead to your symptoms getting worse. Do not stop taking Colcibra unless your doctor tells you to. Your doctor may tell you to reduce the dose over a few days before stopping completely.

Can Colcibra affect my heart?

Risk of heart failure may be lower with Colcibra than with other NSAIDs.

Can Colcibra affects my liver?

Colcibra use liver problems, such as liver damage, hepatitis, and liver failure. These problems can affect how well your liver works. On rare occasions, liver problems can be fatal.

*** Taking medicines without doctor's advice can cause long-term problems.